Xpert® MTB/RIF for smear-negative presumptive TB: impact on case notification in DR Congo
DESIGN: Quasi-experimental design with 86 evaluation and 49 control clinics in Kinshasa, Democratic Republic of Congo. Smear microscopy was supported at all 135 clinics, Xpert was placed in 15 evaluation clinics and a sputum transport system was implemented for 25 satellite clinics. The number of cases notified before and during the project (July 2012–June 2013) was obtained from the National TB Program.
RESULTS: Of 27 147 presumptive TB cases presenting in clinics with access to Xpert, 5922 (21.8%) were smear-positive. Of 18 636 individuals with 3 negative microscopy results, 6920 (37.1%) underwent Xpert testing, 991 (14.3%) of whom tested positive. The number of bacteriologically positive cases increased equally in evaluation clinics (15.1%, 95%CI −2.3 to 32.6) and control clinics (13.6%, 95%CI 2.6–29.3), for a difference in increase of 1.5% (95%CI −28.8 to 31.8). There was no difference in the change in smear-negative cases (−42.4%, 95%CI −111.5 to 26.6), nor in all types of TB notified (−6.1%, 95%CI −32.5 to 20.4) between the evaluation and control clinics.
CONCLUSION: In part due to a restrictive algorithm, Xpert as follow-on to smear microscopy did not increase the overall number of TB notifications, nor the number of bacteriologically positive cases.
Keywords: TB detection; follow-on test; resource-poor settings
Document Type: Research Article
Affiliations: 1: *School of Public Health, University of Kinshasa, Kinshasa 2: †Provincial Coordination of the National TB Programme, Kinshasa, Democratic Republic of Congo 3: †Public Health, TB and HIV Consult, Tilburg, The Netherlands 4: §Stop TB Partnership, Secretariat, Geneva, Switzerland 5: Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 6: Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, Division of Epidemiology, College of Public Health, Ohio State University, Columbus, Ohio, USA
Publication date: February 1, 2016
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content